A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Poole, Danielle N ^a   Tracy, J Kathleen ^b   Levitz, Lauren ^c   Rochas, Mali ^c   Sangare, Kotou ^d   Yekta, Shahla ^e   Tounkara, Karamoko ^c   Aboubacar, Ben ^c   Koita, Ousmane ^d   Lurie, Mark ^a   De Groot, Anne S ^c,e  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GAIA Vaccine Foundation   (United States)

^d UNIVERSITY OF BAMAKO   (Mali)

^e UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; CANCER IMMUNIZATION; CANCER PREVENTION; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALI; MEDICAL PRACTICE; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PATIENT DECISION MAKING; SCHOOL CHILD; SEX DIFFERENCE; URBAN AREA; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; DECISION MAKING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MALI; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT PARTICIPATION; SEXUALLY TRANSMITTED DISEASES, VIRAL; URBAN POPULATION; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84874203487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056402     Document Type: Article

References (44)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
2. Castle PE, Solomon D, Schiffman M, Wheeler CM, Grp A, (2005) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. Journal of the National Cancer Institute 97: 1066-1071.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802.
4. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
5. Haupt RM, Sings HL, (2011) The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health 49: 467-475.
6. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, et al. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373: 1949-1957.
7. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, et al. (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364: 401-411.
8. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
9. Leyva M BT, Tarwater P, (2006) Attitudes towards cervical cancer screening: a study of beliefs among women in Mexico. Californian Journal of Health Promotion 4: 13-24.
10. Markovic M, Kesic V, Topic L, Matejic B, (2005) Barriers to cervical cancer screening: a qualitative study with women in Serbia. Soc Sci Med 61: 2528-2535.
11. Reyes-Ortiz CA, Camacho ME, Markides KS, Kenneth OJ, (2007) Health insurance and cervical cancer screening among older women in Latin American and Caribbean cities. Journal of the American Geriatrics Society 55: S159-S159.
12. Louie KS, de Sanjose S, Mayaud P, (2009) Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 14: 1287-1302.
13. (UNAIDS) JUNPoHA (2010) Global Report, UNAIDS Report on the Global AIDS Epidemic. World Health Organization.
14. Wright TC, Ellerbrock TV, Chiasson MA, Vandevanter N, Sun XW, et al. (1994) Cervical Intraepithelial Neoplasia in Women Infected with Human-Immunodeficiency-Virus- Prevalence, Risk-Factors, and Validity of Papanicolaou Smears. Obstetrics and Gynecology 84: 591-597.
15. Bekele A, Baay M, Mekonnen Z, Suleman S, Chatterjee S, (2010) Human papillomavirus type distribution among women with cervical pathology- a study over 4 years at Jimma Hospital, southwest Ethiopia. Tropical Medicine & International Health 15: 890-893.
16. Kruger-Kjaer S, van den Brule AJC, Svare EI, Engholm G, Sherman ME, et al. (1998) Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. International Journal of Cancer 76: 613-619.
17. Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, et al. (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 100: 1191-1197.
18. Dudgeon MR, Inhorn MC, (2004) Men's influences on women's reproductive health: medical anthropological perspectives. Soc Sci Med 59: 1379-1395.
19. USAID (2007) USAID country health statistical report, Mali. Washington, DC: United States Agency for International Development.
20. Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, et al. (2011) Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis 52: 641-645.
21. Tracy JK, Traore CB, Bakarou K, Dembele R, Coulibaly RC, et al. (2011) Risk factors for high-risk human papillomavirus infection in unscreened Malian women. Tropical Medicine & International Health 16: 1432-1438.
22. Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL, et al. (2002) Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 31: 202-209.
23. Centre WIICoHaCCHI (2012) Human Papillomavirus and Related Cancers in Mali. WHO/ICO.
24. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127: 2893-2917.
25. Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ, (2010) Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues 20: 35-42.
26. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS, (2010) HPV vaccine acceptability among Kenyan women. Vaccine 28: 4864-4867.
27. Arrossi S, Maceira V, Paolino M, Sankaranarayanan R, (2012) Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: a population-based survey. Vaccine 30: 2467-2474.
28. Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano-Ponce E, et al. (2008) Determinants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean. Vaccine 26: L73-L79.
29. Remes P, Selestine V, Changalucha J, Ross DA, Wight D, et al. (2012) A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 30: 5363-5367.
30. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, et al. (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 89: 821-830B.
31. Waller J, McCaffery K, Wardle J, (2004) Beliefs about the risk factors for cervical cancer in a British population sample. Prev Med 38: 745-753.
32. Marshall H, Ryan P, Roberton D, Baghurst P, (2007) A cross-sectional survey to assess community attitudes to introduction of Human papillomavirus vaccine. Aust N Z J Public Health 31: 235-242.
33. Marlow LA, Waller J, Wardle J, (2007) Public awareness that HPV is a risk factor for cervical cancer. Br J Cancer 97: 691-694.
34. Coleman MA, Levison J, Sangi-Haghpeykar H, (2011) HPV vaccine acceptability in Ghana, West Africa. Vaccine 29: 3945-3950.
35. Oh JK, Lim MK, Yun EH, Lee EH, Shin HR, (2010) Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 28: 1854-1860.
36. Leplege A, Schemann JF, Diakite B, Toure O, Ecosse E, et al. (2006) A new condition specific quality of life measure for the blind and the partially sighted in Sub-Saharan Africa, the IOTAQOL: methodological aspects of the development procedure. Qual Life Res 15: 1373-1382.
37. StataCorp (2007) Stata Statistical Software: Release 10. College Station, TX: StataCorp LP.
38. Wong LP, (2011) Knowledge and Attitudes About HPV Infection, HPV Vaccination, and Cervical Cancer Among Rural Southeast Asian Women. International Journal of Behavioral Medicine 18: 105-111.
39. Buys P, Dasgupta S, Thomas TS, (2009) Determinants of a Digital Divide in Sub-Saharan Africa: A Spatial Econometric Analysis of Cell Phone Coverage. World Development 37: 1494-1505.
40. Collumbien M, Hawkes S, (2000) Missing men's messages: does the reproductive health approach respond to men's sexual health needs? Cult Health Sex 2: 135-150.
41. Hawkes S, (1998) Why include men? Establishing sexual health clinics for men in rural Bangladesh. Health Policy Plan 13: 121-130.
42. IPPF. Reproductive Rights 2000; 2000; London.
43. Biddlecom A, Bankole A, Patterson K, (2006) Vaccine for cervical cancer: reaching adolescents in sub-Saharan Africa. Lancet 367: 1299-1300.
44. Sauvain-Dugerdil C, Gakou B, Berthe F, Dieng AW, Ritschard G, Lerch M, (2008) The Start of the Sexual Transition in Mali: Risks and Opportunities. Studies in Family Planning 39: 263-280.